Sugi Predict

Sugi Predict / Compounds / SCHEMBL583356

SCHEMBL583356

SCHEMBL583356

CCOC(=O)C(=CNc1ccnn1Cc1ccc(OC)cc1)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 5/20 0.48
▸ KDM4E B2RXH2 5/20 0.48
▸ GAA P10253 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ DHODH Q02127 2/20 0.47
▸ MAPT P10636 5/20 0.47
▸ LMNA P02545 2/20 0.47
▸ BTK Q06187 1/20 0.47
▸ UCHL1 P09936 1/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NPY1R P25929 1/20 0.46
▸ NPY2R P49146 1/20 0.46
▸ STAT1 P42224 1/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262156 0.90 LMNA (0.44) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL8147796 0.90 LMNA (0.44) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL3743887 0.87 BTK (0.44) BTKUCHL1ALDH1A1NPBWR1MCHR1
SCHEMBL2535567 0.87 LMNA (0.56) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL11789499 0.87 NPSR1 (0.50) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL12993596 0.86 UCHL1 (0.45) NPSR1KDM4EGAASMN1; SMN2MAPT
SCHEMBL17963246 0.85 GAA (0.60) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL14026969 0.84 UCHL1 (0.41) NPSR1KDM4EGAASMN1; SMN2MAPT
SCHEMBL583550 0.82 DHODH (0.57) NPSR1KDM4EGAASMN1; SMN2DHODH
SCHEMBL2794177 0.82 BTK (0.39) NPSR1MAPTBTKUCHL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190352276-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE JOINT STOCK COMPANY "BIOCAD" (RU) 2019-11-21 — — US disclosed
WO-2018092047-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE JOINT STOCK COMPANY "BIOCAD" (RU) 2018-05-24 — — WO disclosed
EP-1921078-B1 MULTIKINASE INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-09 — — EP disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 — — US disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 — — US disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 — — US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 — — EP disclosed
US-20110130403-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2011-06-02 — — US disclosed
CN-101801376-A Pyrazolo (3,4-b) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD 2010-08-11 — — CN disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 — — US disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 — — US disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 — — US disclosed
US-20100048552-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS IRM LLC (BM) 2010-02-25 — — US disclosed
EP-2124943-A1 PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-12-02 — — EP disclosed
WO-2008111009-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-09-18 — — WO disclosed
EP-1921078-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-14 — — EP disclosed
WO-2007134259-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-11-22 — — WO disclosed
EP-1043998-B1 USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-03-07 — — EP disclosed
US-6107305-A Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2000-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048552-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS BMX, FYN, FRK NPSR1 1232/4885KDM4E 2829/4885GAA 2094/4885
US-20100168430-A1 MULTIKINASE INHIBITOR REN, RAF1, CHUK NPSR1 1336/4885KDM4E 1510/4885GAA 2689/4885
US-20110130403-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3B, PDE4B NPSR1 2185/4885KDM4E 1406/4885GAA 815/4885
US-20190352276-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, ABL1, CNKSR1 NPSR1 1155/4885KDM4E 2267/4885GAA 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.